

OMB Number:	3235-0287
Estimated average burden hours per response:	0.5

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person * <u>Priebe Waldemar</u> _____ (Last) (First) (Middle) C/O CNS PHARMACEUTICALS, INC. 100 WEST LOOP SOUTH, SUITE 900 _____ (Street) HOUSTON TX 77027 _____ (City) (State) (Zip)	2. Issuer Name and Ticker or Trading Symbol <u>CNS Pharmaceuticals, Inc. [CNSP]</u>	5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director <input checked="" type="checkbox"/> 10% Owner Officer (give title below) Other (specify below)
	3. Date of Earliest Transaction (Month/Day/Year) 12/06/2022	
	4. If Amendment, Date of Original Filed (Month/Day/Year)	6. Individual or Joint/Group Filing (Check Applicable Line) <input checked="" type="checkbox"/> Form filed by One Reporting Person Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price			
Common Stock	12/06/2022		S		5,500	D	\$2.47	245,605	I	See footnote ⁽¹⁾
Common Stock	12/07/2022		S		5,500	D	\$2.46	240,105	I	See footnote ⁽¹⁾
Common Stock	12/08/2022		S		5,500	D	\$2.4	234,605	I	See footnote ⁽¹⁾
Common Stock	12/09/2022		S		2,798	D	\$2.43	231,807	I	See footnote ⁽¹⁾
Common Stock	03/10/2023		S		5,000	D	\$1.29	226,807	I	See footnote ⁽¹⁾
Common Stock	03/13/2023		S		5,000	D	\$1.3	221,807	I	See footnote ⁽¹⁾
Common Stock	03/14/2023		S		5,000	D	\$1.35	216,807	I	See footnote ⁽¹⁾
Common Stock	03/15/2023		S		5,000	D	\$1.22	211,807	I	See footnote ⁽¹⁾
Common Stock	03/16/2023		S		5,000	D	\$1.24	206,807	I	See footnote ⁽¹⁾
Common Stock	03/17/2023		S		5,000	D	\$1.13	201,807	I	See footnote ⁽¹⁾
Common Stock	03/20/2023		S		5,000	D	\$1.08	196,807	I	See footnote ⁽¹⁾
Common Stock	03/21/2023		S		5,000	D	\$1.1	191,807	I	See footnote ⁽¹⁾
Common Stock	03/22/2023		S		5,000	D	\$1.08	186,807	I	See footnote ⁽¹⁾
Common Stock	03/23/2023		S		10,000	D	\$1.08	176,807	I	See footnote ⁽¹⁾
Common Stock	03/24/2023		S		5,000	D	\$1.08	171,807	I	See footnote ⁽¹⁾
Common Stock	03/27/2023		S		5,000	D	\$1.09	166,807	I	See footnote ⁽¹⁾
Common Stock	03/28/2023		S		10,000	D	\$1.04	156,807	I	See footnote ⁽¹⁾

**Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)**

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)	8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date					

Explanation of Responses:

1. Consists of: (i) shares of common stock held by a limited liability company; and (ii) shares held by Houston Pharmaceuticals, Inc.

/s/ Waldemar Priebe

08/01/2023

** Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.